PRİMER SJÖGREN SENDROMLU BİREYLERDE İNTERFERANSİYEL AKIM TEDAVİSİNİN TÜKÜRÜK BEZİ FONKSİYONU ÜZERİNDEKİ ETKİNLİĞİ: TEK KÖR, RANDOMİZE, KONTROLLÜ ÇALIŞMA

Öz

Amaç: Bu çalışma, interferans akımı (İFA) tedavisinin klinik Pilates egzersizleri (KPE) ile birlikte uygulanmasının primer Sjögren sendromu’nda (pSS) kısa, orta ve uzun vadeli etkilerini araştırmayı amaçladı. Yöntem: Çalışmaya 36 pSS hastası dahil edildi. Katılımcılar rastgele iki gruba ayrıldı [müdahale grubu (aktif İFA tedavisi + KPE) n=18; kontrol grubu (sham İFA tedavisi + KPE) n=18]. Uyarılmamış tükürük akış hızı ölçümü (uyarılmamış TAHÖ), uyarılmış tükürük akış hızı ölçümü (uyarılmış TAHÖ), sağlık değerlendirme anketi (SDA), ağız sağlığı etki profili-14 (ASEP-14), ağız sağlığıyla ilgili yaşam kalitesi-Birleşik Krallık anketi (ASYK-BK), Beck Depresyon Envanteri (BDE), Beck Anksiyete Envanteri (BAE), kısa form-36 (KF-36) ve Pittsburgh Uyku Kalitesi İndeksi (PUKİ) değerlendirme için kullanıldı. Değerlendirmeler tedavi öncesinde ve tedaviden sonra 8., 20., 32. ve 44. haftalarda yapıldı. Her iki tedavi de 8 hafta boyunca haftada 3 kez uygulandı. Bulgular: Tedavi öncesi ve sonrası veriler karşılaştırıldığında, müdahale grubunda uyarılmamış ve uyarılmış TAHÖ değerlerinde iyileşme gözlendi (p<0,001). Her iki grupta da SDA, ASEP-14, ASYK-BK, BDE, BAE, KF-36 (fiziksel ve zihinsel bileşenler) ve PUKİ’de iyileşmeler kaydedildi (p<0,05). Tüm parametrelerin tedavi sonrası fark değerleri karşılaştırıldığında, sonuçlar müdahale grubu lehine anlamlıydı (p<0,05). Uyarılmış ve uyarılmamış TAHÖ, SDA, ASEP-14, ASYK-BK, BDE, BAE, KF-36 ve PUKİ analizlerinde, grup ve zaman-grup etkileşim etkileri anlamlı bulundu (p<0,05). Sonuç: İFA tedavisi, hastalık aktivitesi ve semptomlarda kısa, orta ve uzun vadede güvenle uygulanabilecek etkili bir farmakolojik olmayan tedavi yöntemidir. KPE ise pSS’de psikososyal faktörlerin iyileşmesine olumlu katkı sağlamaktadır.

Anahtar Kelimeler

• Egzersiz
• İnterferansiyel akım
• Tükürük
• Sjögren sendromu
• Kserostomi

THE EFFECTIVENESS OF INTERFERENTIAL CURRENT THERAPY ON SALIVARY GLAND FUNCTION IN INDIVIDUALS WITH PRIMARY SJOGREN’S SYNDROME: SINGLE-BLIND RANDOMIZED, CONTROLLED TRIAL

Abstract

Purpose: This study aimed to investigate short-, mid-, and long-term effects of interferential current (IFC) therapy combined with clinical Pilates exercises (CPE) in primary Sjogren’s syndrome (pSS). Methods: Thirty-six pSS were included. The participants were randomly divided into 2 groups [intervention group (active IFC therapy + CPE) n=18; control group (sham IFC therapy + CPE) n=18]. Unstimulated salivary flow rate measurement (unstimulated SFRM); Stimulated salivary flow rate measurement (stimulated SFRM); health assessment questionnaire (HAQ); Oral Health Impact Profile-14 (OHIP-14); oral health-related quality of life-United Kingdom questionnaire (OHRQOL-UK); Beck Depression Inventory (BDI); Beck Anxiety Inventory (BAI); short form-36 (SF-36), Pittsburgh Sleep Quality Index (PSQI) were used for evaluation. Assessments were conducted pre-treatment and at 8, 20, 32, and 44 weeks post-treatment. Both treatments were applied 3 times weekly for 8 weeks. Results: When the pre- and post-treatment data were compared, improvement was observed in unstimulated SFRM and Stimulated SFRM values in the intervention group (p<0.001). The improvements were also recorded in HAQ, OHIP-14, OHRQOL-UK, BDI, BAI, SF-36 (physical and mental component), and PSQI in both groups (p<0.05). When the difference values of all parameters were compared post treatment, they were significant in favor of intervention group (p<0.05). Analysis of stimulated and unstimulated SFRM, HAQ, OHIP-14, OHRQOL-UK, BDI, BAI, SF-36, and PSQI revealed significant group and time-by-group interaction effects (p<0.05). Conclusion: IFC therapy is an effective non-pharmacological treatment method that can be safely applied in the short-term, med-, and long-term in disease activity and symptoms. CPE contribute positively to the improvement of psychosocial factors in pSS.

Keywords

• Exercise
• Interferential current
• Saliva
• Sjogren’s syndrome
• Xerostomia

References

1. Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open. 2019;5(2):e001064.
2. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983-9.
3. Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology. 2015;54(12):2230-8.
4. Emmelin N. Nerve interactions in salivary glands. J Dent Res. 1987;66(2):509-17.
5. Hasegawa Y, Sugahara K, Sano S, Sakuramoto A, Kishimoto H, Oku Y. Enhanced salivary secretion by interferential current stimulation in patients with dry mouth: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(5):481-9.
6. Ward AR. Electricity, fields and waves in therapy. New South Wales, Australia: Science Press; 1986. p. 232-4.
7. Gil-Montoya JA, Silvestre FJ, Barrios R, Silvestre-Rangil J. Treatment of xerostomia and hyposalivation in the elderly: a systematic review. Med Oral Patol Oral Cir Bucal. 2016;21(3):e355-66.
8. Sivaramakrishnan G, Sridharan K. Electrical nerve stimulation for xerostomia: A meta-analysis of randomised controlled trials. J Tradit Complement Med. 2017;7(4):409-13.

9. Zhang W, Chen Z, Li XM, Gao J, Zhao Y. [Recommendations for the diagnosis and treatment of Sjögren’s syndrome in China]. Zhonghua Nei Ke Za Zhi. 2023;62(9):1059-67.
10. Santos EJF, Farisogullari B, Dures E, Geenen R, Machado PM; EULAR taskforce on recommendations for the management of fatigue in people with inflammatory rheumatic diseases. Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2023;9(3):e0003350. Erratum in: RMD Open. 2023;9(4):e003350corr1.
11. Hackett KL, Deary V, Deane KH, Newton JL, Ng WF, Rapley T. Experience of sleep disruption in primary Sjögren’s syndrome: a focus group study. Br J Occup Ther. 2018;81(4):218-26.
12. Strömbeck B, Ekdahl C, Manthorpe R, Jacobsson LT. Physical capacity in women with primary Sjögren’s syndrome: a controlled study. Arthritis Rheum. 2003;49:681-8.
13. Natour J, Cazotti Lde A, Ribeiro LH, Baptista AS, Jones A. Pilates improves pain, function and quality of life in patients with chronic low back pain: a randomized controlled trial. Clin Rehabil. 2015;29(1):59-68.
14. Mason DK, Harden RM, Boyle JA, Jasani MK, Williamson J, Buchanan WW. Salivary flow rates and iodide trapping capacity in patients with Sjögren’s syndrome. Ann Rheum Dis. 1967;26(4):311-5.
15. Häkkinen A, Kautiainen H, Hannonen P, Ylinen J, Arkela-Kautiainen M, Sokka T. Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(1):59-63.
16. Küçükdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51(1):14-19.
17. Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact Profile. Community Dent Health. 1994;11(1):3-11.
18. Başoğlu ME, Karaağaçlıoğlu L, Yılmaz B. Developing a Turkish Oral Health Impact Profile-OHIP-14-TR. Turkiye Klinikleri J Dental Sci. 2014;20(2):85-92.
19. McGrath C, Bedi R. Population based norming of the UK oral health related quality of life measure (OHQoL-UK). Br Dent J. 2002;193(9):521-4.
20. Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, et al. Oral health related quality of life is affected by disease activity in Behçet’s disease. Oral Dis. 2006;12(2):145-51.
21. Beck AT, Ward CH, Mendelson M, Mock J, ErbaugH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
22. Hisli N. A study on the validity of the Beck Depression Inventory. Turk Psychol J. 1998;6:118-23.
23. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893-7.
24. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck anxiety inventory: psychometric properties. J Cogn Psychother. 1998;12(2):163-72.
25. Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A. Reliability and validity of the Turkish version of short form-36 (SF-36): a study in a group of patients will rheumatic diseases. Turk J Drugs Ther. 1999;12(2):102-6.
26. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
27. Ağargün MY, Kara H, Anlar Ö. The validity and reliability of the Pittsburgh Sleep Quality Index. Türk Psikiyatri Dergisi. 1996;7(2):107-15.
28. Cohen J. Statistical power analysis for the behavioral sciences. Routledge. 2013.
29. Strietzel FP, Lafaurie GI, Mendoza GR, Alajbeg I, Pejda S, Vuletić L, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 2011;63(1):180-90.
30. Chimenos-Kustner E, Marques-Soares MS. Burning mouth and saliva. Med Oral. 2002;7(4):244-53.
31. Fernández-Martínez G, Zamora-Legoff V, Hernández Molina G. Oral health-related quality of life in primary Sjögren’s syndrome. Reumatol Clin (Engl Ed). 2020;16(2).92-6.
32. Rusthen S, Young A, Herlofson BB, Aqrawi LA, Rykke M, Hove LH, et al. Oral disorders, saliva secretion, and oral health‐related quality of life in patients with primary Sjögren’s syndrome. Eur J Oral Sci. 2017;125(4):265-71.
33. Enger TB, Palm Ø, Garen T, Sandvik L, Jensen JL. Oral distress in primary Sjögren’s syndrome: implications for health-related quality of life. Eur J Oral Sci. 2011;119(6):474-80.
34. Koçer B, Tezcan ME, Batur HZ, Haznedaroğlu Ş, Göker B, İrkeç C, et al. Cognition, depression, fatigue, and quality of life in primary Sjögren’s syndrome: correlations. Brain Behav. 2016;6(12):e00586.
35. Inal V, Kitapcioglu G, Karabulut G, Keser G, Kabasakal Y. Evaluation of quality of life in relation to anxiety and depression in primary Sjögren’s syndrome. Mod Rheumatol. 2010;20(6):588-97.
36. Kotsis K, Voulgari PV, Tsifetaki N, Drosos AA, Carvalho AF, Hyphantis T. Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren’s syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2014;34:1671-81.
37. Strömbeck BE, Theander E, Jacobsson LT. Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren’s syndrome. Rheumatology (Oxford). 2007;46(5):868-71.
38. Ng WF, Miller A, Bowman SJ, Price EJ, Kitas GD, Pease C, et al. Physical activity but not sedentary activity is reduced in primary Sjögren’s syndrome. Rheumatol Int. 2017;37(4):623-31.
39. Liu Z, Dong Z, Liang X, Liu J, Xuan L, Wang J, et al. Health-related quality of life and psychological status of women with primary Sjögren’s syndrome: a cross-sectional study of 304 Chinese patients. Medicine (Baltimore). 2017;96(50):e9208.
40. Chung SW, Hur J, Ha YJ, Kang EH, Hyon JY, Lee HJ, et al. Impact of sleep quality on clinical features of primary Sjogren’s syndrome. Korean J Intern Med. 2019;34(5):1154-64.